Isis Pharmaceuticals Director Sells $509,800 in Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) Director Joseph H. Wender unloaded 10,000 shares of the stock on the open market in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $50.98, for a total value of $509,800.00. Following the sale, the director now directly owns 31,135 shares in the company, valued at approximately $1,587,262. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded down 3.49% on Friday, hitting $48.42. 1,145,267 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 1-year low of $12.95 and a 1-year high of $51.72. The stock has a 50-day moving average of $42.24 and a 200-day moving average of $34.35. The company’s market cap is $5.620 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last released its earnings data on Tuesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was up 103.4% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.52 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ISIS shares. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note to investors on Wednesday. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Tuesday. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $39.50.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.